298 Mitral valve repair is the key in surgical treatment of primary dilated cardiomyopathy with heart failure

2006 ◽  
Vol 5 (1) ◽  
pp. 69-69
Author(s):  
N RADOVANOVIC ◽  
B MIHAJLOVIC ◽  
S NICIN ◽  
Z JONJEV ◽  
L PETROVIC ◽  
...  
2020 ◽  
Vol 21 (1) ◽  
pp. 52-60 ◽  
Author(s):  
Tomás Benito-González ◽  
Rodrigo Estévez-Loureiro ◽  
Pedro A. Villablanca ◽  
Patrizio Armeni ◽  
Ignacio Iglesias-Gárriz ◽  
...  

2011 ◽  
Vol 142 (3) ◽  
pp. 569-574.e1 ◽  
Author(s):  
Michael A. Acker ◽  
Mariell Jessup ◽  
Steven F. Bolling ◽  
Jae Oh ◽  
Randall C. Starling ◽  
...  

2003 ◽  
Vol 35 (1) ◽  
pp. 463-465 ◽  
Author(s):  
S.-S Wang ◽  
R.-B Hsu ◽  
Y.-S Chen ◽  
W.-J Ko ◽  
N.-K Chou ◽  
...  

2017 ◽  
Vol 65 (3) ◽  
Author(s):  
Mathias Orban ◽  
Martin Orban ◽  
Daniel Braun ◽  
Michael Nabauer ◽  
Steffen Massberg ◽  
...  

Author(s):  
Abu Ghosh Z ◽  
◽  
Beeri R ◽  
Falah B ◽  
Pertz A ◽  
...  

Oncology patients with Heart Failure (HF) and severe Mitral Regurgitation (MR) are often considered to have a prohibitive risk for surgical mitral valve repair/replacement. We describe a patient with active multiple myeloma and significant HF and MR who was treated with MitraClip, which improved symptoms and allowed delivery of optimal oncological treatment.


2018 ◽  
Vol 379 (24) ◽  
pp. 2307-2318 ◽  
Author(s):  
Gregg W. Stone ◽  
JoAnn Lindenfeld ◽  
William T. Abraham ◽  
Saibal Kar ◽  
D. Scott Lim ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Alberto Polimeni ◽  
Michele Albanese ◽  
Nadia Salerno ◽  
Iolanda Aquila ◽  
Jolanda Sabatino ◽  
...  

Abstract Percutaneous mitral valve repair has been increasingly performed worldwide after approval. We sought to investigate predictors of clinical outcome in patients with mitral regurgitation undergoing percutaneous valve repair. The MITRA-UMG study, a single-centre registry, retrospectively collected consecutive patients with symptomatic moderate-to-severe or severe MR undergoing MitraClip therapy. The primary endpoint was the composite of cardiovascular death or rehospitalization for heart failure. Between March 2012 and July 2018, a total of 150 consecutive patients admitted to our institution were included. Procedural success was obtained in 95.3% of patients. The composite primary endpoint of cardiovascular death or rehospitalization for HF was met in 55 patients (37.9%) with cumulative incidences of 7.6%, 26.2%, at 30 days and 1-year, respectively. In the Cox multivariate model, NYHA functional class and left ventricular end-diastolic volume index (LVEDVi), independently increased the risk of the primary endpoint at long-term follow-up. At Kaplan–Meier analysis, a LVEDVi > 92 ml/m2 was associated with an increased incidence of the primary endpoint. In this study, patients presenting with dilated ventricles (LVEDVi > 92 ml/m2) and advanced heart failure symptoms (NYHA IV) at baseline carried the worst prognosis after percutaneous mitral valve repair.


2015 ◽  
Vol 21 (10) ◽  
pp. S157
Author(s):  
Yukiko Mizutani ◽  
Shunsuke Kubo ◽  
Makar Moody ◽  
Mamoo Nakamura ◽  
Takahiro Shiota ◽  
...  

2020 ◽  
Vol 17 (2) ◽  
pp. 93-102
Author(s):  
Martin Orban ◽  
Enzo Lüsebrink ◽  
Daniel Braun ◽  
Thomas J. Stocker ◽  
Erik Bagaev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document